AOD 9604 vs HGH Frag 176-191 compared: structure, stability, clinical data, dosing, and legal status. Learn how these two HGH peptides actually differ.
AOD-9604 and HGH Frag 176-191 are two synthetic peptides built from the same 16-amino-acid tail of human growth hormone, and the practical difference between them comes down to one added amino acid. AOD-9604 is the stabilized, tyrosine-extended version of that fragment; HGH Frag 176-191 is the unmodified fragment itself. Both are studied for fat metabolism, and neither is FDA-approved for human use in the United States.
What Is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone corresponding to residues 176-191, with a tyrosine added at the front end for stability. It was developed by an Australian pharmaceutical company and moved through Phase II clinical trials as a weight-loss drug candidate.
What makes AOD-9604 interesting in the research literature is its selectivity. Studies describe it as stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (new fat formation) without driving growth, appetite, or blood-sugar changes the way full HGH does.
Because it does not appear to raise IGF-1 in the published human data, most of the aod 9604 vs hgh discussion online comes back to one question: can you get the fat-loss effect without the hormone's systemic risks?
What Is HGH Frag 176-191?
HGH Frag 176-191 is the natural 16-amino-acid sequence found at the end of the human growth hormone molecule. Researchers identified this region because it seemed to carry much of HGH's fat-metabolizing activity on its own.
Unlike AOD-9604, the plain fragment was never developed into a patented drug with company-funded trials. It exists today almost entirely in the research-peptide market as a lyophilized powder, which means the published human evidence is thin.
AOD-9604 vs HGH Frag 176-191: Side-by-Side Comparison
| Feature | AOD-9604 | HGH Frag 176-191 |
|---|---|---|
| Structure | hGH 176-191 plus an N-terminal tyrosine | Native hGH 176-191 sequence |
| Development | Engineered drug candidate, patented | Natural fragment, not patented as a drug |
| Human clinical trials | Phase II obesity trials, program discontinued | No large controlled human trials |
| Stability | More resistant to enzymatic breakdown | Degrades faster in solution |
| IGF-1 effect | No significant rise in studied doses | Limited human data |
| Dosing pattern | Once daily in most community protocols | Often split into two daily doses |
| Regulatory status | Not FDA-approved; banned by WADA | Not FDA-approved; banned by WADA |
How They Differ in Practice
Stability and reconstitution
Stability is the most obvious real-world difference. The extra tyrosine in AOD-9604 is designed to slow enzymatic degradation, so the peptide tends to hold up better after reconstitution than the plain fragment.
People who report aod-9604 gelling up are usually describing a handling error rather than a bad batch. Adding diluent too quickly, using the wrong solution, or shaking the vial instead of swirling it can all cause clumping, and reconstituted peptide should be refrigerated and protected from light.
Dosing and handling
Community protocols for both peptides land in a similar range: roughly 250 to 500 micrograms per day, injected subcutaneously, often on an empty stomach. A typical aod 9604 dosage protocol schedules the injection in the morning before fasted cardio, based on the theory that lipolysis is already elevated.
HGH Frag 176-191 is sometimes split into two smaller injections because its active window is short. Neither peptide has an FDA-approved dose, so any number circulating online is an anecdotal estimate rather than a clinical standard.
What the Evidence Actually Shows
AOD-9604 has the stronger paper trail of the two. It went through controlled human trials, and the results were modest enough that the obesity program was shelved rather than submitted for approval.
Online aod 9604 reviews are largely anecdotal and mixed, with some users describing gradual fat loss and others reporting nothing noticeable. HGH Frag 176-191 has even less to go on, since almost all of its data comes from animal and cell studies.
There is also a mechanism question worth separating out. In a sermorelin vs aod 9604 comparison, sermorelin acts upstream by prompting the pituitary to release growth hormone, which raises IGF-1, while AOD-9604 is designed not to do that. That single difference explains why the two peptides get discussed for very different purposes.
Safety, Legality, and Research Status
Both peptides are sold as research chemicals, not medications. Neither AOD-9604 nor HGH Frag 176-191 is FDA-approved for human use, and both appear on the World Anti-Doping Agency prohibited list.
Reported side effects in trials and user reports are generally mild — injection-site irritation, headache, and occasional nausea — but the long-term safety profile of either peptide is not established.
Anyone considering these compounds should treat them as unapproved substances and talk with a licensed healthcare professional first. Self-dosing with research-grade peptides carries real risks around purity, sterility, and dosing accuracy.
Bottom Line
- AOD-9604 and HGH Frag 176-191 share the same 16-amino-acid core, but AOD-9604 carries an extra tyrosine that makes it more stable.
- AOD-9604 has actual human trial data; HGH Frag 176-191 has very little.
- Neither peptide is FDA-approved, and both are banned in sport.
- Common community dosing for both is 250–500 mcg per day while fasted, though no clinical standard exists.
- User results are inconsistent, and AOD-9604's own clinical development program was discontinued.
Frequently Asked Questions
Is AOD-9604 the same as HGH Frag 176-191?
They are closely related but not identical. AOD-9604 is the human growth hormone 176-191 fragment with an added tyrosine at the N-terminus, which makes it more resistant to enzymatic breakdown. HGH Frag 176-191 is the unmodified version of that same sequence, so the core region is the same while stability and research history differ.
Which is better for fat loss, AOD-9604 or HGH Frag 176-191?
No head-to-head human trial has ever compared the two peptides, so there is no evidence-based winner. AOD-9604 has more human data because it went through company-sponsored Phase II obesity trials, but those results were modest and the program was discontinued. Online user reports for both compounds are anecdotal and inconsistent.
Is AOD-9604 legal in the United States?
AOD-9604 is not FDA-approved for human use and is not a lawful prescription medication in the US. It is typically sold as a research chemical for laboratory use only, and it is prohibited by the World Anti-Doping Agency. Importing or using it for personal consumption sits in a legally gray area and carries purity and sterility risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.